KR20230097110A - 항-타우 항체의 안전한 투여 방법 - Google Patents

항-타우 항체의 안전한 투여 방법 Download PDF

Info

Publication number
KR20230097110A
KR20230097110A KR1020237017905A KR20237017905A KR20230097110A KR 20230097110 A KR20230097110 A KR 20230097110A KR 1020237017905 A KR1020237017905 A KR 1020237017905A KR 20237017905 A KR20237017905 A KR 20237017905A KR 20230097110 A KR20230097110 A KR 20230097110A
Authority
KR
South Korea
Prior art keywords
tau
amino acid
seq
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017905A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 헨리
파르타 낸디
카를로스 페레스 루이소
링쥬 리
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20230097110A publication Critical patent/KR20230097110A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020237017905A 2020-10-26 2021-10-25 항-타우 항체의 안전한 투여 방법 Pending KR20230097110A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105810P 2020-10-26 2020-10-26
US63/105,810 2020-10-26
US202163250114P 2021-09-29 2021-09-29
US63/250,114 2021-09-29
PCT/EP2021/079566 WO2022090169A1 (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Publications (1)

Publication Number Publication Date
KR20230097110A true KR20230097110A (ko) 2023-06-30

Family

ID=78483271

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017905A Pending KR20230097110A (ko) 2020-10-26 2021-10-25 항-타우 항체의 안전한 투여 방법

Country Status (10)

Country Link
US (1) US20220127346A1 (cg-RX-API-DMAC7.html)
EP (1) EP4232472A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023546503A (cg-RX-API-DMAC7.html)
KR (1) KR20230097110A (cg-RX-API-DMAC7.html)
AU (1) AU2021370222A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199808A1 (cg-RX-API-DMAC7.html)
IL (1) IL302383A (cg-RX-API-DMAC7.html)
MX (1) MX2023004832A (cg-RX-API-DMAC7.html)
TW (1) TW202231661A (cg-RX-API-DMAC7.html)
WO (1) WO2022090169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗PHF-Tau抗體及其用途
WO2021242757A1 (en) * 2020-05-26 2021-12-02 The Trustees Of The University Of Pennsylvania Monocolonal antibodies against pathological tau, and methods using same
AU2021367878A1 (en) * 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Also Published As

Publication number Publication date
EP4232472A1 (en) 2023-08-30
TW202231661A (zh) 2022-08-16
MX2023004832A (es) 2023-07-18
WO2022090169A1 (en) 2022-05-05
CA3199808A1 (en) 2022-05-05
US20220127346A1 (en) 2022-04-28
IL302383A (en) 2023-06-01
AU2021370222A1 (en) 2023-06-22
JP2023546503A (ja) 2023-11-02

Similar Documents

Publication Publication Date Title
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
JP2024037893A (ja) アルツハイマー病治療方法
US20230123110A1 (en) High dose treatments for alzheimer's disease
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
TW202434633A (zh) 治療甲狀腺眼疾之方法
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
EP3269376B1 (en) Treatment and prevention of alzheimer's disease (ad)
HK40100358A (en) Method of safe administration of anti-tau antibody
CN116829582A (zh) 安全施用抗Tau抗体的方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
HK40100364A (en) Methods of reducing tau in human subjects
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
WO2026085535A2 (en) Treatment of pathologies associated with down syndrome with anti-fsh antibodies
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
TW202535463A (zh) Anca相關血管炎之治療
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40067504A (en) High dose treatments for alzheimer's disease
HK40068762A (en) High dose treatments for alzheimer's disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902